Two pivotal cell therapy programs are advancing, with LYL273 showing strong efficacy and improved safety in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Major data updates and regulatory milestones are expected in the next 12 months.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.